Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $260.0 million.

  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) fell 334.57% to $260.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year decrease of 519.36%. This contributed to the annual value of $1.0 billion for FY2025, which is 538.24% down from last year.
  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) amounted to $260.0 million in Q4 2025, which was down 334.57% from $249.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Depreciation & Amortization (CF) high stood at $376.0 million for Q1 2021, and its period low was $244.0 million during Q1 2025.
  • For the 5-year period, Teva Pharmaceutical Industries' Depreciation & Amortization (CF) averaged around $292.7 million, with its median value being $291.5 million (2023).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Depreciation & Amortization (CF) crashed by 2015.71% in 2021, and later skyrocketed by 1737.7% in 2022.
  • Teva Pharmaceutical Industries' Depreciation & Amortization (CF) (Quarter) stood at $320.0 million in 2021, then fell by 4.38% to $306.0 million in 2022, then fell by 13.07% to $266.0 million in 2023, then grew by 1.13% to $269.0 million in 2024, then decreased by 3.35% to $260.0 million in 2025.
  • Its last three reported values are $260.0 million in Q4 2025, $249.0 million for Q3 2025, and $251.0 million during Q2 2025.